Posted inHematology-Oncology news Oncology
Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma
This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating alloSCT for high-risk cases.